Anti-thyroid-stimulating hormone receptor autoantibody (TRAb) (TRAb)

Anti-thyroid-stimulating hormone receptor autoantibodies (TRAb) are pathogenic immunoglobulins that target the TSH receptor (TSHR) on thyroid follicular cells (Smith & Hegedüs, 2019, Nature Reviews Endocrinology). These antibodies are the primary cause of Graves' disease, where they typically function as agonists that mimic the action of thyroid-stimulating hormone (TSH), leading to hyperthyroidism and goiter (StatPearls, 2023, Graves Disease). In some clinical presentations, TRAb can also act as "blocking" antibodies, preventing TSH from binding and leading to hypothyroidism (Furmaniak et al., 2015, Autoimmunity Highlights). Furthermore, TRAb are implicated in Graves' ophthalmopathy (thyroid eye disease) by stimulating TSH receptors located on orbital fibroblasts and adipocytes, which triggers inflammation and tissue expansion (Douglas et al., 2020, New England Journal of Medicine). Modern therapeutic approaches focus on neutralizing these antibodies directly or reducing their circulating levels. For instance, the monoclonal antibody K1-70 acts as a direct TSHR antagonist to block TRAb activity (Kahaly et al., 2020, JCEM). Other strategies include using FcRn inhibitors like efgartigimod to accelerate the clearance of these pathogenic IgGs from the bloodstream (ClinicalTrials.gov, 2024). These interventions aim to restore euthyroidism and reduce the extrathyroidal manifestations of Graves' disease.

Other names

Thyroid-stimulating hormone receptor antibodyTSHR-AbThyroid-stimulating immunoglobulinTSIThyroid-blocking immunoglobulinTBITSH-binding inhibitory immunoglobulinTBIILong-acting thyroid stimulatorLATS

Therapeutic interventions target these autoantibodies through several mechanisms: direct competitive antagonism at the TSH receptor to prevent antibody-mediated activation (Kahaly et al., 2020), depletion of CD20-positive B-cells to reduce the production of new autoantibodies (Salvi et al., 2007), and inhibition of the neonatal Fc receptor (FcRn) to accelerate the catabolism and clearance of circulating IgG autoantibodies (Ling et al., 2023).